Abstract:A randomized trial allows estimation of the causal effect of an intervention compared to a control in the overall population and in subpopulations defined by baseline characteristics. Often, however, clinical questions also arise regarding the treatment effect in subpopulations of patients, which would experience clinical or disease related events post-randomization. Events that occur after treatment initiation and potentially affect the interpretation or the existence of the measurements are called {\it intercurrent events} in the ICH E9(R1) guideline. If the intercurrent event is a consequence of treatment, randomization alone is no longer sufficient to meaningfully estimate the treatment effect. Analyses comparing the subgroups of patients without the intercurrent events for intervention and control will not estimate a causal effect. This is well known, but post-hoc analyses of this kind are commonly performed in drug development. An alternative approach is the principal stratum strategy, which classifies subjects according to their potential occurrence of an intercurrent event on both study arms. We illustrate with examples that questions formulated through principal strata occur naturally in drug development and argue that approaching these questions with the ICH E9(R1) estimand framework has the potential to lead to more transparent assumptions as well as more adequate analyses and conclusions. In addition, we provide an overview of assumptions required for estimation of effects in principal strata. Most of these assumptions are unverifiable and should hence be based on solid scientific understanding. Sensitivity analyses are needed to assess robustness of conclusions.

Identifiability of Causal Effects on a Binary Outcome Within Principal Strata

Identification and estimation of causal effects in the presence of confounded principal strata

Identifiability and estimation of causal effects by principal stratification with outcomes truncated by death

Principal Causal Effect Identification and Surrogate End Point Evaluation by Multiple Trials

Principal causal effect identification and surrogate endpoint evaluation by multiple trials

Principal stratification in causal inference.

Identifying Principal Stratum Causal Effects Conditional on a Post-treatment Intermediate Response

Principal Stratification with Continuous Post-Treatment Variables: Nonparametric Identification and Semiparametric Estimation

Principal stratification in causal inference

Identifiability of causal effects for binary variables with baseline data missing due to death.

Partial identification of principal causal effects under violations of principal ignorability

Identifiability of Causal Effects for Binary Variables with Baseline Data Missing Due to Death

Principal stratification analysis of noncompliance with time-to-event outcomes

Weighted Approach for Estimating Effects in Principal Strata with Missing Data for a Categorical Post-Baseline Variable in Randomized Controlled Trials

Identifiability, Stratification and Minimum Variance Estimation of Causal Effects

Principal stratification with continuous treatments and continuous post-treatment variables

Principal Stratification with Time-to-Event Outcomes

Selection bias in the treatment effect for a principal stratum

Principal Stratum Strategy: Potential Role in Drug Development

Bayesian Nonparametrics for Principal Stratification with Continuous Post-Treatment Variables

Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by post-randomization events